Pain
-
The aim of this nationwide survey was to evaluate the extent of pain problems, the principles of pain management and the use of newer drug delivery techniques in terminal cancer patients. 'Terminal period' was defined as an expected life span of about 2 weeks. Another aim was to evaluate the level of knowledge of physicians and nurses and to assess their educational needs regarding management of cancer pain. A total of 456 questionnaires were sent to chairmen and head nurses of 6 major specialties (228 departments) that treat cancer patients in Sweden. ⋯ More than 50% of physicians and nurses admit that they have inadequate knowledge about pain evaluation techniques, newer analgesics and newer drug delivery systems. More aggressive use of opioids administered by more humane routes and better use of adjuvant therapy can be expected to improve pain management for the terminal patient. There is also a need for better physician and nurse education.
-
Twenty-one patients with post-mastectomy pain syndrome (PMPS) were entered in an open-label trial of topical 0.025% capsaicin treatment (3 daily applications for 2 months). Out of 19 evaluable patients, 2 (10.5%) reported complete disappearance of all symptoms, and 11 (57.9%) had a reduction of pain which was never worse than mild at the end of treatment. ⋯ This is the first independent confirmation of the usefulness of capsaicin in the PMPS, following the recent publication of a randomized, placebo-controlled clinical study showing significant pain relief with 0.075% capsaicin but not with vehicle cream. Further experimental and clinical research on the properties of capsaicin in other painful peripheral neuropathies is desirable.
-
Three cases are described in which phantom limb pain was successfully treated with ketamine hydrochloride. Possible mechanisms for this observation are suggested.
-
Twenty-six patients with extensive gynecologic, colorectal or genitourinary cancer who suffered uncontrolled, incapacitating pelvic pain were enrolled in this study during a 1-year period. All the patients receiving oral opioids who developed poor pain response due to the progression of disease or untoward side effects necessitating other modes of therapy were eligible to participate. Bilateral percutaneous neurolytic superior hypogastric plexus blocks with 10% phenol were performed in every patient, 1 day after receiving successful diagnostic blocks using 0.25% bupivacaine (BUP). ⋯ No complications related to the block were experienced by any patient. In conclusion, neurolytic superior hypogastric plexus block was both effective in relieving pain in 69% of the patients studied (95% confidence interval of 48-85%). Additional neurolytic blocks using higher volumes of the neurolytic agent may be needed in patients with extensive retroperitoneal disease, a group in whom moderate or poor results should be expected.
-
Randomized Controlled Trial Clinical Trial
Is TENS purely a placebo effect? A controlled study on chronic low back pain.
Although high-frequency low-intensity transcutaneous electric nerve stimulation (TENS) has been extensively used to relieve low back pain, experimental studies of its effectiveness have yielded contradictory findings mainly due to methodological problems in pain evaluation and placebo control. In the present study, separate visual analog scales (VAS) were used to measure the sensory-discriminative and motivational-affective components of low back pain. Forty-two subjects were randomly assigned to 1 of 3 groups: TENS, placebo-TENS, and no treatment (control). ⋯ This additive effect was not found for placebo-TENS. When evaluated at home, pain intensity was significantly reduced more by TENS than placebo-TENS 1 week after the end of treatment, but not 3 months and 6 months later. At home evaluation of pain unpleasantness in the TENS group was never different from the placebo-TENS group.(ABSTRACT TRUNCATED AT 250 WORDS)